NCT06799026 - A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2030

Conditions

Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma

Interventions

DRUG

Elranatamab

Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.

BIOLOGICAL

GM-CSF

Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.

BIOLOGICAL

DC/MM Fusion Vaccine

Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.

Trial Locations (2)

RECRUITING

Beth Israel Deaconess Medical Center, Boston

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston